Chromium Picolinate For Insulin Resistance In Subjects With HIV Disease: A Pilot Study
| Effect | None |
| Trial Design | Cohort |
| Trial Length | 1-6 months |
| Number of Subjects | 8 |
| Sex | Both Genders |
| Age Range | 30-44, 45-64 |
| Body Types | Overweight |
In persons with HIV (where drug therapy is associated with increased risk for insulin resistance) given supplemental chromium at 1mg daily as picolinate, supplementation was associated with a 25% increase in glucose disposal rate as assessed by hyperinsulinaemic–euglycaemic insulin clamp.
There was no influence on viral titres or lymphocytes, and two persons experienced increases in liver enzymes (relationship to chromium uncertain).
